TY  - JOUR
AU  - Paz-Ares, Luis
AU  - Vicente, David
AU  - Tafreshi, Ali
AU  - Robinson, Andrew
AU  - Soto Parra, Hector
AU  - Mazières, Julien
AU  - Hermes, Barbara
AU  - Cicin, Irfan
AU  - Medgyasszay, Balazs
AU  - Rodríguez-Cid, Jerónimo
AU  - Okamoto, Isamu
AU  - Lee, SungSook
AU  - Ramlau, Rodryg
AU  - Vladimirov, Vladimir
AU  - Cheng, Ying
AU  - Deng, Xuan
AU  - Zhang, Ying
AU  - Bas, Tuba
AU  - Piperdi, Bilal
AU  - Halmos, Balazs
PY  - 2020
DO  - 10.1016/j.jtho.2020.06.015
UR  - http://hdl.handle.net/10668/15844
T2  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
AB  - In the randomized KEYNOTE-407 study (ClinicalTrials.gov, NCT02775435), pembrolizumab plus carboplatin and paclitaxel/nab-paclitaxel (chemotherapy) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo...
LA  - en
KW  - Chemotherapy
KW  - PD-L1
KW  - Pembrolizumab
KW  - Squamous non–small-cell lung cancer
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carcinoma, Squamous Cell
KW  - Humans
KW  - Lung Neoplasms
TI  - A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407.
TY  - research article
VL  - 15
ER  -